Despite most patients being clinically unaffected by ALT elevations on treatment, we still demonstrated an overall risk of 3.4% for DILI on standard TB therapy and higher rates of DILI among those patients with enzyme elevations at randomisation compared with the overall trial population. Here, GPT is linked to tuberculosis.